Clinical Trial

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-12; most recent amendment 2024-05-02.
Status change: Not Yet Recruiting → Recruiting 2024-05-02
Trial Details
NCT Number NCT06218628
Lead Sponsor Fox Chase Cancer Center
Conditions Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
Enrollment 24 participants
Start Date 2024-04-05
Primary Completion 2029-08-22 (estimated)
Study Completion 2030-08-27 (estimated)
Updated on ClinicalTrials.gov 2024-05-03